HeartFlow

HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » Więcej na de.investing.com

Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » Więcej na de.investing.com

Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » Więcej na de.investing.com